Cyclacel Pharmaceuticals regains compliance with Nasdaq minimum bid price rule

Cyclacel Pharmaceuticals announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market on January 4, 2024, indicating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules. As previously disclosed on July 7, 2023, the Company received a letter from the Listing Qualifications Staff of Nasdaq notifying the Company that Nasdaq had granted the Company a 180-day extension, or until January 2, 2024, to regain compliance with the requirement for the Company’s common stock, par value $0.001 per share, to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). On January 4, 2024, the Company received a minimum bid price compliance letter from the Staff confirming the Company has regained compliance with Listing Rule 5550(a)(2), and that the matter is now closed.